Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Nasopharyngeal Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
28 drugs · 154 active trials
1 drug · 6 active trials
1 drug · 21 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 24 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Cediranib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-02 |
| Doxorubicin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 15, 2004 |
| Erlotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-06 |
| Infigratinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 1, 2018 |
| Pazopanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-08 |
| Temoporfin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-01 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-11 |
| Tranilast | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 20, 2022 |
| Zoledronic Acid | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-09 |
| Azacitidine | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Mar 3, 2006 |
| Irinotecan | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-12 |
| Valproic Acid | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-04 |
| Alvespimycin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-07 |
| Buparlisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 29, 2014 |
| Everolimus | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-11 |
| Filgrastim | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2001-07 |
| Hydroxyurea | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2001-07 |
| Lenalidomide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 10, 2011 |
| Gefitinib | Phase not stated | N/A | 0 | 0 | 0 | 1 | 0 | — | — | 2003-08 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.